Trial Profile
A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Triptorelin (Primary) ; Integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Immune System Regulation
- 11 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 11 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Aug 2021.
- 13 Oct 2020 According to an Immune System Regulation media release, the infection clinics have been fully occupied with caring for Corona patients during the ongoing pandemic and the Medical Products Agency has advised against inclusion in clinical trials and the company can now speed up patient recruitment to the study.